16,050 Shares in Stryker Corporation $SYK Purchased by Stonebridge Capital Management Inc.

Stonebridge Capital Management Inc. bought a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,050 shares of the medical technology company’s stock, valued at approximately $5,053,000. Stryker accounts for 2.4% of Stonebridge Capital Management Inc.’s holdings, making the stock its 13th biggest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Varma Mutual Pension Insurance Co boosted its position in Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after purchasing an additional 5,100 shares during the period. QRG Capital Management Inc. increased its position in Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after acquiring an additional 4,186 shares during the period. Swedbank AB raised its stake in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after acquiring an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after acquiring an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SYK shares. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Needham & Company LLC decreased their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Down 0.2%

SYK stock opened at $330.08 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The firm has a market capitalization of $126.61 billion, a P/E ratio of 34.21, a P/E/G ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company’s 50 day simple moving average is $328.37 and its 200-day simple moving average is $331.72.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the business posted $3.13 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Insider Buying and Selling

In other Stryker news, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.